We are one of the very few independent scientific teams with sufficient expertise and resources to develop our own COVID-19 program - a vaccine (ACvac1) and an antibody treatment (ACmab1). In the global race for a vaccine, this is unique.
Let’s build a world where people take matters into their own hands
We are a private biotech company independent of big pharmaceutical industry. Building on 21 years of research in Alzheimer’s disease, initiated by Prof. Novak’s team after his discovery of key pathological changes of tau proteins at Laboratory of Molecular Biology, MRC, Cambridge, UK in 1988, we are now putting our proprietary technology to use to develop our own vaccine and antibody treatment against COVID-19.
There is a global race for a cure against COVID-19. We have developed two alternative solutions to fight the global pandemic. Our vaccine ACvac1 is unique because it contains only functionally important pieces of the target viral protein, thus limiting negative side-effects after treatment and stimulating the immune system. In comparison to other vaccine candidates, our solution is tailored to elderly population and people with immunodeficiencies, who are especially vulnerable to the COVID-19. Our monoclonal antibody ACmab1 is a laboratory-made protein that mimics the immune system’s ability to fight off the virus SARS-CoV-2. ACmab1 demonstrated the ability to completely neutralize the live virus in first trials.
Using our previous technology platform, we can get to clinical trials and ultimately the product approvals much more effectively and in a much shorter time. We want to stay independent and open the project to people for investment. Support us now and be part of the first independent COVID-19 programme in the world.
Discovery of tau proteins by Prof. Novak in a team of Nobel Prize laureates at MRC Cambridge.
Prof. Novak co-founded AXON Neuroscience to use his groundbreaking discovery in the research of Alzheimer‘s disease.
The first tau vaccine AADvac1 entered into the clinical trials
Positive phase II results with the world's first Tau Vaccine for Alzheimer's Disease - AADvac1
First exploratory use of Axon’s vaccine platform to develop a vaccine against COVID-19.
April - September 2020
Patent and pre-clinical trials
Investors can begin investing in the project from this website.
Public announcement of a new potential antibody therapy ACmab1 against COVID-19 showing strong ability to completely neutralize the virus SARS-CoV-2.
Subscription period successfully finished
First-in-human clinical trials (planned).
Send us an email or call and we will be happy to talk some more.